- Conditions: Cardiac Disease; Coronary Artery Disease
Intervention: Device: CELT ACD
Sponsors: Vasorum Ltd; Vasorum Ltd
Not yet recruiting - verified May 2012 - Condition: Hemophilia A
Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Biological: PEGylated Recombinant Factor VIII
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; Baxter Innovations GmbH
Recruiting - verified May 2012 - Condition: Neuroendocrine Tumors
Intervention: Drug: RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Knee Osteoarthritis
Interventions: Drug: SAR113945; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
Sponsors: Charite University, Berlin, Germany; JSehouli; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Conditions: Diabetics Mellitus Type 1; Diabetes Mellitus Type 2
Intervention: Device: InsuPad
Sponsors: Insuline Medical Ltd.; Insuline Medical Ltd.
Not yet recruiting - verified May 2012 - Condition: Concussed Athletes
Intervention: Behavioral: tDCS
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany
Recruiting - verified May 2012 - Condition: Healthy Subjects
Interventions: Device: Litramine; Device: Placebo
Sponsors: InQpharm Group; InQpharm Group
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: FTY720
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Mild to Moderate Psoriasis
Interventions: Other: TTOP; Other: non-TTOP
Sponsors: Reich, Kristian, M.D.; Kristian Reich, MD; LEO Pharma
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Interventions: Drug: N(t)RTI) + boosted protease inhibitors (PI/r); Drug: maraviroc + boosted protease inhibitors (PI/r); Drug: maraviroc + N(t)RTI)
Sponsors: Kirby Institute; Kirby Institute
Not yet recruiting - verified April 2012 - Condition: Mini-Stroke
Intervention: Behavioral: Patient centered structured support program
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany; Technische Universität München; University of Erlangen-Nürnberg Medical School; Praxis für Neurologie und Psychiatrie am Prinzregentenplatz, München; Berlin University of Technology
Recruiting - verified April 2012 - Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab; Drug: Omalizumab; Drug: Placebo
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel; Drug: Paclitaxel
Sponsors: German Breast Group; German Breast Group; Celgene GmbH; Roche Pharma AG
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: TMC647055; Drug: TMC647055; Drug: TVR; Drug: TVR; Drug: TVR; Drug: PegFN; Drug: RBV
Sponsors: Janssen R&D Ireland; Janssen Infectious Diseases Research & Development Ireland
Not yet recruiting - verified April 2012 - Condition: Actinic Keratosis
Interventions: Drug: Resiquimod; Drug: Placebo / Vehicle; Drug: Resiquimod; Drug: Resiquimod
Sponsors: Spirig Pharma Ltd.; Spirig Pharma Ltd.
Not yet recruiting - verified April 2012 - Condition: Menstrual Pain
Intervention: Procedure: Self-care acupressure at three predefined points
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany; Karl and Veronica Carstens Foundation
Not yet recruiting - verified April 2012 - Condition: Acute Vertigo
Interventions: Drug: V0251; Drug: placebo
Sponsors: Pierre Fabre Medicament; Pierre Fabre Medicament
Not yet recruiting - verified April 2012 - Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified April 2012 - Condition: Neuroendocrine Tumors
Interventions: Drug: RAD001; Drug: SOM230
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: End Stage Renal Disease; Inflammation
Interventions: Device: HCO1100; Device: P210H
Sponsors: Gambro Dialysatoren GmbH; Gambro Dialysatoren GmbH
Not yet recruiting - verified April 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924; Drug: NN9924
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: tiotropium; Drug: olodaterol; Drug: olodaterol; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium; Drug: olodaterol; Drug: tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Atopic Dermatitis
Interventions: Drug: REGN668; Other: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Biological: rVIIa-FP; Biological: Placebo (0.9% normal saline)
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2012 - Conditions: Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic
Interventions: Drug: Investigational new drug company code: SAF312 placebo; Drug: Investigational new drug company code: SAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Carcinoma Breast Stage IV
Intervention: Drug: BIBW 2992 in combination with vinorelbine
Sponsors: University of Magdeburg; University of Magdeburg; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified February 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: olodaterol; Drug: Tiotropium; Drug: Tiotropium; Drug: Oldaterol; Drug: Tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Actinic Keratoses; Squamous Cell Carcinomas
Interventions: Device: MD-3511356; Other: Standard Sun Protection Measures
Sponsors: Spirig Pharma Ltd.; Spirig Pharma Ltd.
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium+olodaterol; Drug: tiotropium + olodaterol (high dose); Drug: placebo to tiotropium+olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz; Roche Pharma AG
Not yet recruiting - verified April 2012 - Conditions: Total Hip Arthroplasty; Muscle Injury
Interventions: Biological: PLX-PAD low dose; Biological: PLX-PAD high dose; Biological: Placebo
Sponsors: Pluristem Ltd.; Pluristem Ltd.
Not yet recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025; Drug: Placebo to IGE025
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Metastatic Renal Cell Carcinoma (mRCC)
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Procedure: Spirometry
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: BI 655064; Drug: BI 655064; Drug: Placebo to BI 655064; Drug: Placebo to BI 655064
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir + peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Available - verified April 2012 - Condition: Familial Chylomicronemia Syndrome (FCS)
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Superficial Vein Thrombosis
Interventions: Drug: Rivaroxaban; Drug: Fondaparinux
Sponsors: GWT-TUD GmbH; GWT-TUD GmbH; Bayer
Recruiting - verified April 2012 - Condition: Pelvic Organ Prolapse
Interventions: Procedure: Elevate Mesh; Procedure: Anterior Colporrhaphy
Sponsors: Mayo Clinic; Emanuel Trabuco; American Medical Systems
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Telaprevir; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Alzheimer's Disease
Interventions: Drug: BMS-241027; Drug: BMS-241027; Drug: BMS-241027; Drug: Placebo matching BMS-241027
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Colitis, Ulcerative
Interventions: Drug: Kappaproct; Drug: Placebo
Sponsors: InDex Pharmaceuticals; InDex Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders; Anti-Dyskinesia Agents
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: Placebo; Drug: boceprevir; Drug: boceprevir; Drug: boceprevir; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: TVR
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide; Drug: Placebo
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Recruiting - verified February 2012 - Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerCondition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release (CBZ-CR)
Sponsors: UCB, Inc.; UCB, Inc.; EDEV S.À.R.L
Not yet recruiting - verified May 2012 - Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide; Drug: Placebo; Drug: Formoterol Fumarate
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Recruiting - verified October 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Bronchial Asthma
Intervention: Drug: Ciclesonide
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Actinic Keratosis
Interventions: Drug: Ingenol mebutate; Drug: Placebo Gel
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified May 2012 - Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified May 2012 - Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin placebo; Drug: linagliptin placebo; Drug: metformin; Drug: placebo metformin; Drug: metformin; Drug: linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium + olodaterol; Drug: tiotropium; Drug: tiotropium; Drug: olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: afq056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Juvenile Idiopahtic Arthritis
Intervention: Drug: etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Drug: TR-701 FA for 6 days followed by 4 days of placebo; Drug: Linezolid for 10 days of treatment
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: Hypertension
Intervention:
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo to Secukinumab (AIN457); Biological: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Osteogenesis Imperfecta
Interventions: Drug: BPS804; Other: Untreated reference group
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Acromegaly
Intervention: Drug: Active oral octreotide study drug therapy
Sponsors: Chiasma, Inc.; Chiasma, Inc.
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus Type 2
Interventions: Drug: Vildagliptin; Drug: Sitagliptin
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Drug: Tiotropium
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Lung Transplantation
Interventions: Drug: standard therapy; Drug: Everolimus (RAD001) as add-on
Sponsors: Novartis; Novartis Pharmaceuticals; Crolll Gmbh
Recruiting - verified April 2012 - Condition: Hepatic Impairment
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Persistent Fetal Circulation Syndrome
Interventions: Drug: Bosentan; Drug: Matching placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Conditions: Crohn's Disease; Ileitis; Ileo-colonic and Colonic Crohn's Disease; Granulomatous Colitis; Regional Enteritis
Interventions: Procedure: lumbar puncture; Drug: lumbar puncture
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate; Drug: Placebo
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2012 - Condition: Nocturnal Enuresis
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals; Ferring Arzneimittel GmbH
Recruiting - verified April 2012 - Condition: Smoking Cessation
Interventions: Drug: Varenicline Tartrate; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg; Drug: SOM230 LAR 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Kidney Transplantation
Interventions: Drug: Tofacitinib; Drug: Tofacitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention: Dietary Supplement: diet intervention
Sponsors: German Diabetes Center; German Diabetes Center
Recruiting - verified May 2012 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus
Interventions: Drug: Darunavir; Drug: Ritonavir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Basal Cell Carcinoma
Intervention: Drug: vismodegib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011 - Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011 - Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe; Drug: Canakinumab lyophilized cake; Drug: Triamcinolone Acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: BMS-833923
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Crohn's Disease
Interventions: Drug: QAX576; Drug: Infliximab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Hypertension; Chronic Kidney Disease
Intervention: Drug: Valsartan
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: MEK162 + RAF265
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention: Other: Blood samples
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Intervention: Drug: Ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Pulmonary Fibrosis
Interventions: Drug: placebo; Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus; Macular Edema
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Renal Artery Obstruction
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: rituximab [MabThera/Rituxan]; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: JNJ-40411813; Drug: JNJ-40411813 or Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Interventions: Drug: Ambrisentan - low dose; Drug: Ambrisentan - high dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Central Neuropathic Pain; Multiple Sclerosis
Intervention: Drug: AVP-923
Sponsors: Avanir Pharmaceuticals; Avanir Pharmaceuticals
Recruiting - verified May 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Bronchiectasis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2011 - Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Overactive Bladder; Bladder, Overactive; Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Overactive Bladder
Interventions: Drug: Fesoterodine 8mg; Drug: Fesoterodine 4mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: rituximab [MabThera]; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Pulmonary Disease, Chronic Obstructive; Cardiovascular Disease
Interventions: Drug: fluticasone furoate/vilanterol; Drug: fluticasone furoate; Drug: vilanterol; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Severe COPD
Intervention: Drug: Daxas
Sponsors: Nycomed; Nycomed
Recruiting - verified May 2012 - Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Colitis, Ulcerative
Interventions: Biological: Anrukinzumab; Biological: Anrukinzumab; Biological: Anrukinzumab; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Marginal Zone Lymphoma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone Palmitate
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: tiotropium low dose; Drug: tiotropium high dose; Drug: placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified May 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Dementia Alzheimer's Type
Interventions: Drug: SAR110894D; Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
Interventions: Drug: MP4OX; Drug: Saline
Sponsors: Sangart; Sangart
Recruiting - verified May 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Attention Deficit/Hyperactivity Disorder
Interventions: Drug: Placebo; Drug: RIT124D; Drug: RIT124D; Drug: RIT124D
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: tiotropium Respimat low dose; Drug: tiotropium Respimat high dose; Drug: placebo Respimat
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012 - Condition: Spondylitis, Ankylosing
Interventions: Biological: etanercept; Drug: Background NSAID; Other: PLACEBO; Drug: Background NSAID
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: AFQ056; Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release
Sponsors: UCB, Inc.; UCB, Inc.; EDEV S.À.R.L
Recruiting - verified May 2012 - Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Drug: Atomoxetine Hydrochloride; Drug: Placebo Comparator
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Smoking Cessation
Interventions: Drug: Varenicline; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets; Other: Best Available Therapy (BAT)
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: CP 690,550 5 mg; Drug: CP 690,550 10 mg; Biological: Etanercept 50 mg; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Other: Any MMY treatment
Sponsors: Janssen Pharmaceutica N.V., Belgium; Janssen Pharmaceutica N.V., Belgium
Recruiting - verified April 2012 - Condition: Cancer Cachexia
Intervention: Drug: MT-102
Sponsors: Myotec Therapeutics Ltd; Myotec Therapeutics Ltd; Veeda Oncology
Recruiting - verified April 2012 - Condition: Pancreatic Neoplasms
Intervention: Drug: BAY86-9766+Gemcitabine
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: CNTO 148 (Golimumab); Biological: CNTO 148 (golimumab) or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Schering-Plough (Ireland) Company
Recruiting - verified April 2012 - Condition: Dupuytren's Contracture
Intervention: Drug: Xiapex
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Amyloidosis
Interventions: Drug: KIACTA (eprodisate disodium); Drug: Placebo
Sponsors: C.T. Development America, Inc.; C.T. Development America, Inc.
Recruiting - verified May 2012 - Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Mabthera intravenous; Drug: MabThera subcutaneous
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Kidney Disease, Chronic
Interventions: Drug: Mircera; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib [Tarceva]; Drug: Erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906; Drug: erlotinib; Drug: placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Coronary Disease
Intervention: Device: TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter
Sponsors: TriReme Medical, Inc.; TriReme Medical, Inc.
Recruiting - verified April 2012 - Condition: Crohn's Disease
Interventions: Biological: Infliximab; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Myocardial Infarction
Interventions: Drug: Eplerenone; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012 - Condition: Psoriatic Arthritis
Intervention: Biological: AIN457A
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: Olanzapine; Drug: Flupentixol; Drug: Quetiapine; Drug: Aripiprazole; Drug: Haloperidol
Sponsors: University of Bremen; University of Bremen; German Federal Ministry of Education and Research
Recruiting - verified April 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Enalapril
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: PRAME-positive; Melanoma; Metastatic Melanoma
Intervention: Biological: Immunotherapeutic GSK2302025A, different formulations
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: GastroEsophageal Cancer
Interventions: Drug: Lapatinib; Drug: Lapatinib plus capecitabine
Sponsors: National Center for Tumor Diseases, Heidelberg; National Center for Tumor Diseases, Heidelberg
Recruiting - verified May 2012 - Condition: Liver Transplantation
Interventions: Drug: MMF(1000mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (200mg bid) + tacrolimus + standard of care medications; Drug: sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Non-small-cell Lung Cancer
Intervention: Drug: AUY922
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207217; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Acute Ischemic Stroke
Intervention: Device: NeuroThera® Laser System
Sponsors: PhotoThera, Inc; PhotoThera, Inc
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Renal Transplantation
Interventions: Drug: Everolimus; Drug: Prograf or Neoral
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: docetaxel; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified May 2012 - Condition: Heart Failure
Interventions: Device: Medtronic PrimeADVANCED Neurostimulator; Device: Medtronic PrimeADVANCED Neurostimulator
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified January 2012 - Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric PsoriasisCondition: Psoriasis
Intervention: Drug: Etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention: Procedure: Blood collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Eltrombopag olamine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Biological: ustekinumab/placebo; Biological: ustekinumab/placebo; Biological: ustekinumab/placebo
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012 - Conditions: Immune System Diseases; Autoimmune Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases; Connective Tissue Disease
Interventions: Biological: CDP7657; Other: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Conditions: Cystocele; Uterine Prolapse
Intervention: Device: TiLOOP® Total 6 (Surgical mesh implantation)
Sponsors: pfm medical ag; pfm medical ag; Aix Scientifics; GfE Medizintechnik GmbH
Recruiting - verified May 2012 - Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: rituximab [Mabthera/Rituxan]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Influenza
Interventions: Drug: Tamiflu; Drug: Tamiflu
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Colitis, Ulcerative
Intervention: Drug: GSK1399686
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Sexual Dysfunction, Physiological; Ejaculation
Interventions: Drug: Dapoxetine hydrochloride; Other: Alternate care/non-dapoxetine hydrochloride treatment(s)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Chronic Kidney Disease Stage 3 and 4
Interventions: Drug: Zemplar (paricalcitol) Capsules; Drug: Placebo capsules
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified April 2012 - Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120; Drug: BIBF 1120; Drug: Sorafenib; Drug: Sorafenib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Bial - Portela C S.A.; Sunovion
Recruiting - verified May 2012 - Condition: Influenza
Intervention: Drug: Tamiflu
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium +salmeterol+ fluticasone high dose; Drug: Tiotropium+salmeterol+ fluticasone high,med, low, placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Renal Transplantation
Interventions: Drug: Everolimus, Basiliximab; Drug: Enteric Coated Mycophenolate Sodium, Cyclosporine A
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Interventions: Drug: ACC-001+ QS21; Drug: ACC-001; Drug: ACC-001 + QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin]; Drug: irinotecan; Drug: temozolomide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781); Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781); Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012 - Condition: Hemophilia A
Interventions: Drug: moroctocog alfa (AF-CC) (ReFacto AF); Procedure: Laboratory tests
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Heart Transplantation
Interventions: Drug: MMF OR Myfortic, Certican®, Sandimmun® optoral; Drug: Sandimmun Optoral, Certican
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Arthroplasty, Replacement; Thromboembolism
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Fibrosis; Renal Impairment
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Progressive Sarcoma
Intervention: Drug: Everolimus/RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAIONCondition: Optic Neuropathy, Ischemic
Intervention: Drug: No intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Leukemia, Myeloid, Acute
Interventions: Drug: BI 6727 (d1 and 15); Drug: BI 6727 (d1 and 15); Drug: Cytarabine; Drug: Cytarabine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Carcinoma; Renal Cell; Non Clear Cell Renal Carcinoma; Papillary Cell Renal Carcinoma; Adenocarcinoma
Intervention: Drug: RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hypertension, Pulmonary
Intervention: Drug: ambrisentan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Clopidogrel; Drug: Placebo
Sponsors: Deutsches Herzzentrum Muenchen; Deutsches Herzzentrum Muenchen
Recruiting - verified April 2012 - Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified August 2010 - Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012 - Condition: Myocardial Infarction
Interventions: Drug: tenecteplase; Drug: enoxaparin; Drug: clopidogrel; Procedure: catheterisation; Procedure: primary PCI
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Ankylosing Spondylitis
Intervention: Drug: Etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Epilepsy
Interventions: Drug: Lacosamide; Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012 - Condition: Kidney Transplantation
Interventions: Drug: Everolimus; Drug: Myfortic and Neoral
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Invasive Fungal Infection; Aspergillosis
Interventions: Drug: Isavuconazole; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2012 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Bosentan; Drug: Sildenafil Citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
 |
Join Clinical Trials that are Held in Berlin, Germany |
Clinical Trial Locations 